TRANSDERMAL LOCAL ANESTHETIC PATCH WITH INJECTION PORT

• US 20090311311A1
• Filed: 12/18/2008
• Published: 12/17/2009
• Est. Priority Date: 06/16/2008
• Status: Active Grant

• Current Assignee: Erica Shantha, Jessica Shantha, Lauren Shantha, Totada R. Shantha
• Original Assignee: Erica Shantha, Jessica Shantha, Lauren Shantha, Totada R. Shantha
• Inventors: Shantha, Jessica, Shantha, Totada R., Shantha, Lauren, Shantha, Erica
• Granted Patent: US 7,883,487 B2
• Time in Patent Office: Days
• US Class Current: 424/449
• CPC Class Codes: A61K 9/703 characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
• CPC Class Codes: A61P 29/00 Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Abstract

Described herein are transdermal delivery devices composed of at least one re-sealable injection port and at least one local anesthetic reservoir. The device effectively delivers anesthetic to the skin of the subject prior to puncturing the skin by syringes, needle sticks, or other instruments intended to be inserted into the skin. In addition, this device can be used to deliver various therapeutic agents for either locally or systemically.

Claims

1. A transdermal delivery device comprising at least one re-sealable injection port and at least one local anesthetic reservoir for delivering the anesthetic to the skin of a subject.

2. The transdermal delivery device of claim 1, wherein the device comprises a patch comprising (a) a replaceable button, wherein the replaceable button comprises a local anesthetic reservoir;

and (b) an injection port for receiving the replaceable button.

3. The transdermal delivery device of claim 1, wherein the device further comprises at least one re-sealable refill port for refilling the local anesthetic reservoir.

4. The transdermal delivery device of claim 1, wherein the device comprises a first side and second side, wherein the first side comprises an impermeable material surrounding the injection port, the second side comprises a permeable or semi-permeable material, wherein the impermeable material of the first side and the permeable or semi-permeable material of the second side forms the local anesthetic reservoir, and the permeable or semi-permeable material permits the diffusion of the local anesthetic from the local anesthetic reservoir.

5. The transdermal delivery device of claim 4, wherein the periphery of the permeable or semi-permeable material on the second side is surrounded by a second impermeable material.

6. The transdermal delivery device of claim 5, wherein an adhesive is present on the surface of the second impermeable material.

7. The transdermal delivery device of claim 4, wherein one or more re-sealable refill ports are present on the first side of the device.

8. The transdermal delivery device of claim 4, wherein the device comprises two or more injection ports.

9. The transdermal delivery device of claim 1, wherein the local anesthetic comprises an ester based local anesthetic, an amide based local anesthetic, or a combination thereof.

10. The transdermal delivery device of claim 9, wherein the amide based local anesthetic comprises articaine, bupivacaine, dibucaine, lidocaine, mepivacaine, prilocaine, ropivacaine, or any combination thereof.

11. The transdermal delivery device of claim 9, wherein the amide based local anesthetic comprises lidocaine, prilocaine, or a combination thereof.

12. The transdermal delivery device of claim 11, wherein when lidocaine and prilocaine are present, they are present in at least a ratio of 2:

1 by weight.

13. The transdermal delivery device of claim 9, wherein the ester based local anesthetic comprises benzocaine, chloroprocaine, proparacaine, tetracaine, or any combination thereof.

14. The transdermal delivery device of claim 1, wherein an antiseptic agent is coated on at least one surface of the at least one re-sealable injection port.

15. The transdermal delivery device of claim 1, wherein an antiseptic agent is coated on both surfaces of the at least one re-sealable injection port.

16. The transdermal delivery device of claim 14, wherein the antiseptic agent, antimicrobial agent, antifungal agent, or antiviral agent comprises an alcohol, a quaternary ammonium compounds comprising benzalkonium chloride, cetyl trimethylammonium bromide, boric acid, chlorhexidine gluconate, hydrogen peroxide, iodine, mercurochrome, octenidine dihydrochloride, sodium chloride, sodium hypochlorite, silver nitrate, or any combination thereof.

17. The transdermal delivery device of claim 1, wherein the further comprising one or more therapeutic agents admixed with the local anesthetic.

18. The transdermal delivery device of claim 1, wherein the therapeutic agent comprises a vasoconstrictor, a skin permeability enhancer, an anti-inflammatory agent, an antihistamine, or any combination thereof.

19. The transdermal delivery device of claim 18, wherein the vasoconstrictor comprises phenylephrine, ephedrine sulfate, epinephrine, naphazoline, neosynephrine, vasoxyl, oxymetazoline, or any combination thereof.

20. The transdermal delivery device of claim 18, wherein the skin permeability enhancer comprises dimethyl sulfoxide, lecithin, decyl methyl sulfoxide, dodecyl dimethyl phosphine oxide, octyl methyl sulfoxide, nonyl methyl sulfoxide, undecyl methyl sulfoxide, lauryl alcohol, diisopropyl sebacate, oleyl alcohol, diethyl sebacate, dioctyl sebacate, dioctyl azelate, hexyl laurate, ethyl caprate, butyl stearate, dibutyl sebacate, dioctyl adipate, propylene glycol dipelargonate, ethyl laurate, butyl laurate, ethyl myristate, butyl myristate, isopropyl palmitate, isopropyl isostearate, 2-ethyl-hexyl pelargonate, butyl benzoate, benzyl benzoate, benzyl salicylate, dibutyl phthalate, or any combination thereof.

21. The transdermal delivery device of claim 18, wherein the anti-inflammatory agent comprises celecoxib, meloxicam, nabumetone, piroxicam, naproxen, oxaprozin, rofecoxib, sulindac, ketoprofen, valdecoxib, or any combination thereof.

22. The transdermal delivery device of claim 1, further comprising a short acting anesthetic, a long acting anesthetic, or any combination thereof having a predetermined volume.

23. A method for reducing or eliminating pain associated with a syringe, needle stick, or lancet stick comprising (a) applying the transdermal delivery device of claim 1 on the surface of the skin of a subject for a sufficient time to numb the skin, and (b) inserting the syringe, needle stick, or lancet stick in the resealable injection port.

24. A method for reducing or eliminating pain comprising applying the transdermal delivery device of claim 1 to the skin wherein the skin is bruised, cut, irritated by poison ivy, insect stings, bites or localized skin diseases, or affected by allergic reactions without using the injection port.